About: Taste and Smell Disorders in COVID-19 Patients: Role of Interleukin-6

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Taste and Smell Disorders in COVID-19 Patients: Role of Interleukin-6 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Taste and Smell Disorders in COVID-19 Patients: Role of Interleukin-6
Creator	Serio, Francesca Procacci, Vito Cazzolla, Angela Ciavarella, Domenico Crincoli, Vito De Ruvo, Caterina Lo Muzio, Lorenzo Lovero, Roberto Palmieri, Giuseppe Pepe, Maria Pozzessere, Pietro Santacroce, Luigi Schirinzi, Annalisa Testa, Nunzio Comite, Mariasevera
Source	Medline; PMC
abstract	[Image: see text] The rapid recovery of smell and taste functions in COVID-19 patients could be attributed to a decrease in interleukin-6 levels rather than central nervous system ischemic injury or viral damage to neuronal cells. To correlate interleukin-6 levels in COVID-19 patients with olfactory or gustatory dysfunctions and to investigate the role of IL-6 in the onset of these disorders, this observational study investigated 67 COVID-19 patients with taste or smell disorders or both, who did not require intensive care admission, admitted at COVID Hospital of Policlinico of Bari from March to May 2020. Interleukin-6 was assayed in COVID-19 patients with taste or smell disturbances at the time of admission and at the time of swab negativization. At the same time, patients have been given a specific survey to evaluate the severity of taste and smell disturbances. Of 125 patients with smell or taste dysfunctions at onset of disease, 67 fulfilled the inclusion criteria, while 58 were excluded because 35 of them required intensive care admission, 5 were unable to answer, 5 died, 7 had finished chemotherapy recently, and 5 refused to participate. The evaluation of taste and smell disorders was carried out using a survey performed at the time of admission and at the time of swab negativization. Sinonasal outcome test 22 (SNOT-22) was used as a reference for olfactory function assessment, and Taste and Smell Questionnaire Section of the US NHANES 2011–2014 protocol (CDC 2013b) was used as reference for gustatory function assessment. A venous blood sample was taken for each patient to measure IL-6 levels upon entry and at swab negativization. Interleukin-6 levels in COVID-19 patients in relation to olfactory or gustatory disorders were correlated from the time of their admission to the time of swab negativization. Statistically significant correlations were obtained between the decrease of interleukin-6 levels and the improvement of smell (p value < 0.05) and taste (p = 0.047) functions at swab negativization. The acquired results demonstrate the key role of interleukin-6 in the pathogenesis of chemosensitive disorders in COVID-19 patients.
has issue date	2020-08-04(xsd:dateTime)
bibo:doi	10.1021/acschemneuro.0c00447
bibo:pmid	32786309
has license	no-cc
sha1sum (hex)	e2532176399f929f8f314837f37cc4d37ea67681
schema:url	https://doi.org/10.1021/acschemneuro.0c00447
resource representing a document's title	Taste and Smell Disorders in COVID-19 Patients: Role of Interleukin-6
has PubMed Central identifier	PMC7437448
has PubMed identifier	32786309
schema:publication	ACS Chem Neurosci
resource representing a document's body	covid:e2532176399f929f8f314837f37cc4d37ea67681#body_text
is schema:about of	named entity 'HAVE' named entity 'RAPID' covid:arg/e2532176399f929f8f314837f37cc4d37ea67681 named entity 'COVID-19' named entity 'observational study' named entity 'COVID-19' named entity 'COVID-19' named entity 'COVID-19' named entity 'smell or taste' named entity 'gustatory' named entity 'neuronal cells' named entity 'IL-6' named entity 'COVID-19' named entity 'NHANES' named entity 'Interleukin-6' named entity 'interleukin-6' named entity 'venous blood' named entity 'gustatory' named entity 'IL-6' named entity 'COVID-19' named entity 'intensive care' named entity 'interleukin-6' named entity 'intensive care' named entity 'DID' named entity 'RECOVERY' named entity 'SMELL' named entity 'COULD BE' named entity 'SMELL DISORDERS' named entity 'REFUSED TO PARTICIPATE' named entity 'IL-6' named entity 'ROLE' named entity 'Statistically significant' named entity 'olfactory' named entity 'gustatory' named entity 'RECENTLY' named entity 'INVESTIGATED' named entity 'TIME' named entity 'EVALUATE' named entity 'RATHER' named entity 'ASSESSMENT' named entity 'REQUIRED' named entity 'TASTE' named entity 'ENTRY' named entity 'USED' named entity 'FUNCTIONS' named entity 'olfactory' named entity 'KEY' named entity 'OBSERVATIONAL STUDY' named entity 'CORRELATIONS' named entity 'FINISHED' named entity 'SEVERITY' named entity 'OBTAINED' named entity 'PATIENTS' named entity 'EVALUATION' named entity 'CARRIED' named entity 'DECREASE' named entity 'MARCH' named entity 'chemotherapy' named entity 'ischemic injury' named entity 'pathogenesis' named entity 'central nervous' named entity 'CDC' named entity 'olfactory function' named entity 'Interleukin-6' named entity 'interleukin-6' named entity 'TEST' named entity 'INCLUSION CRITERIA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software